Northland Capmk Analysts Boost Earnings Estimates for BLFS

BioLife Solutions, Inc. (NASDAQ:BLFS) – Equities researchers at Northland Capmk raised their Q3 2025 earnings per share estimates for shares of BioLife Solutions in a research report issued on Monday, March 3rd. Northland Capmk analyst C. Byrnes now forecasts that the medical equipment provider will post earnings of $0.00 per share for the quarter, up from their prior estimate of ($0.01). The consensus estimate for BioLife Solutions’ current full-year earnings is ($0.30) per share. Northland Capmk also issued estimates for BioLife Solutions’ Q4 2025 earnings at $0.01 EPS.

BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.32. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The company had revenue of $22.71 million for the quarter, compared to analysts’ expectations of $21.73 million. During the same period in the previous year, the firm earned ($0.21) EPS.

A number of other research analysts have also recently commented on BLFS. Northland Securities boosted their price target on BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a report on Wednesday, January 8th. Craig Hallum upped their price objective on BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. TD Cowen upped their price objective on BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Benchmark reaffirmed a “buy” rating and set a $30.00 price objective on shares of BioLife Solutions in a report on Thursday, December 19th. Finally, KeyCorp upped their price objective on BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a report on Friday, December 13th. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. According to MarketBeat, BioLife Solutions currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.43.

BioLife Solutions Stock Up 5.7 %

NASDAQ BLFS opened at $26.25 on Wednesday. The stock’s 50 day moving average is $26.67 and its 200 day moving average is $25.48. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. BioLife Solutions has a 12 month low of $14.84 and a 12 month high of $29.55. The stock has a market cap of $1.22 billion, a PE ratio of -24.76 and a beta of 1.91.

Insider Activity at BioLife Solutions

In other BioLife Solutions news, EVP Aby J. Mathew sold 7,604 shares of the company’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $27.33, for a total value of $207,817.32. Following the transaction, the executive vice president now owns 276,315 shares of the company’s stock, valued at $7,551,688.95. This represents a 2.68 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Troy Wichterman sold 987 shares of the company’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $27.02, for a total value of $26,668.74. Following the completion of the transaction, the chief financial officer now directly owns 121,779 shares in the company, valued at $3,290,468.58. This trade represents a 0.80 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 11,978 shares of company stock worth $322,724. Company insiders own 2.20% of the company’s stock.

Hedge Funds Weigh In On BioLife Solutions

Hedge funds have recently bought and sold shares of the business. State Street Corp grew its position in BioLife Solutions by 7.3% in the 3rd quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock valued at $35,364,000 after acquiring an additional 95,788 shares during the last quarter. Geode Capital Management LLC grew its position in shares of BioLife Solutions by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider’s stock worth $21,107,000 after buying an additional 18,473 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in shares of BioLife Solutions by 40.8% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 19,463 shares of the medical equipment provider’s stock worth $487,000 after buying an additional 5,638 shares in the last quarter. Barclays PLC grew its position in shares of BioLife Solutions by 20.1% during the 3rd quarter. Barclays PLC now owns 64,423 shares of the medical equipment provider’s stock worth $1,613,000 after buying an additional 10,803 shares in the last quarter. Finally, D.A. Davidson & CO. bought a new position in shares of BioLife Solutions during the 3rd quarter worth $1,018,000. Institutional investors own 93.24% of the company’s stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.